YGYuxiang Gu

Yuxiang Gu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuxiang Gu has a total of 314 co-authors. Here are the top co-authors by number of shared publications:

  • Heng Yang

    Department of Neurosurgery, Huashan Hospital of Fudan University, Shanghai, People's Republic of China

    33 shared publications
  • Jiabin Su

    Department of Neurosurgery, Huashan Hospital of Fudan University, Shanghai, People's Republic of China

    31 shared publications
  • Wei Ni

    Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China

    31 shared publications
  • Xinjie Gao

    Department of Neurosurgery, Huashan Hospital of Fudan University, Shanghai, People's Republic of China

    23 shared publications
  • Wei Ni

    Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China

    22 shared publications
  • Hanqiang Jiang

    Department of Neurosurgery, Huashan Hospital of Fudan University, Shanghai, People's Republic of China

    18 shared publications

Latest Publications

  • Standalone middle meningeal artery embolization versus Burr-hole surgery in nonacute subdural hematomas and selection strategy based on hematoma volume: A MAGIC-MT trial secondary analysis

    by Ruiyuan Weng, Heng Yang, Dengliang Wang, Jiabin Su, Xinjie Gao, Hanqiang Jiang, Chao Gao, Meng Zhang, Lei Chang, Shengjun Zhou, et al.

    Background and objectives: Middle meningeal artery embolization (MMAE) has emerged as an alternative technique with minimally invasive nature in nonacute subdural hematomas (NASDH). However, whether MMAE alone can replace burr-hole surgery (BHS) remains unclear. Methods: This exploratory secondary study used data from the MAGIC-MT randomized controlled trial to compare standalone MMAE and BHS. The primary outcomes were symptomatic recurrence and progression of hematomas. Overlap weighting (OW) was used to balance baseline variables between groups. Propensity score matching (PSM) was used as sensitivity analysis. Results: A total of 291 BHS and 77 MMAE patients were included. After balancing baseline features, the incidence of primary outcomes in MMAE was significantly higher than that in BHS (OW: 10.9% vs 3.2%, P=0.021; PSM: 10.7% vs 0%, P=0.027). Hematoma volume was an independent risk factor to predict the primary outcomes (adjusted OR, 1.02 (1.01–1.03), P=0.001). In the subgroup with hematoma volume 0.999). Moreover, patients benefited from standalone MMAE with shorter length of hospital stay (OW: P=0.011, PSM: P=0.001). However, in the subgroup with hematoma volume >98 mL, standalone MMAE showed a significantly higher rate of primary outcomes than BHS (OW: 23.5% vs 8.2%, P=0.049; PSM: 23.8% vs 0%, P=0.021). Conclusion: Given the advantage of its minimally invasive nature and low primary outcome rates when hematoma volume is 98 mL, standalone MMAE cannot be routinely recommended to replace BHS.


  • Open Access

    Unusual Synchronous Arbitrary‐Gate Doppler Spectra Enable Intraoperative Hemodynamic Warning of Cerebral Hyperperfusion Syndrome on Moyamoya Disease

    by Xiandi Zhang, Wei Ni, Xing Hu, Heng Yang, Jiabin Su, Hanqiang Jiang, Chao Gao, Ruiyuan Weng, Zhen Fan, Yiming Li, et al.

    Background: Cerebral hyperperfusion syndrome (CHS) is a serious complication following revascularization in moyamoya disease (MMD) patients, yet reliable predictors remain scarce. This study aims to evaluate subcortical hemodynamics intraoperatively using a novel ultrasound imaging technique, synchronous arbitrary gate spectral Doppler (SAGSD), and to identify indicators associated with CHS. Methods: A total of thirty adult MMD patients undergoing revascularization were included. Intraoperative SAGSD imaging, conventional Doppler ultrasound, and indocyanine green videoangiography (ICG‐VA) were performed to assess subcortical hemodynamics at multiple sites before and after anastomosis. Results: All thirty patients underwent revascularization, and five of the six CHS patients exhibited a distinctive “mountain” sign on SAGSD, characterized by three or more discrete velocity peaks within a single cardiac cycle observed simultaneously across two or more sampling sites. The CHS patients showed a significant increase in velocity‐time integral (VTI) change (median Δ + 0.48 cm [95% CI, 0.31 to 0.65], p < 0.001) post‐anastomosis on SAGSD, while conventional Doppler showed no significant change in flow velocity (all p > 0.05). Notably, in CHS patients, ICG‐VA showed no statistical difference in flow velocity, delay, and time to peak after anastomosis (all p > 0.05), whereas SAGSD demonstrated hemodynamic changes such as VTI (median Δ + 0.67 cm [95% CI, 0.43–0.90], p < 0.001) via Doppler spectrum. Conclusion: SAGSD enables highly sensitive, multi‐position, and contrast‐free hemodynamic evaluation of deep cerebral microvasculature. The “mountain” sign, a novel spectral morphology corroborated by quantitative VTI elevation, is a specific intraoperative biomarker strongly associated with CHS, offering a potential predictor for early intervention and improved surgical outcomes.


  • Open Access

    Silencing MALAT1 represses pathological progression, inflammation, and vascular smooth muscle cell phenotype switching by regulating the SEMA3C-mediated Smad pathway in intracranial aneurysms

    by Junlong Kang, Wei Li, Xinjie Gao, Xinhua Tian, Wei Feng, Xiang Yao, Feng Wei, Luyue Chen, Hongjin Chen, Junjiang Tong, et al.

    Background: The crucial role of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in regulating aneurysm formation, inflammation, and neural dysfunction has gradually been recognized. This study aimed to evaluate the effects of MALAT1 modification on pathological changes, inflammation, vascular smooth muscle cell (VSMC) phenotype switching, and the underlying mechanism in intracranial aneurysms (IAs). Methods: MALAT1-overexpressing (oeMALAT1), MALAT1 short hairpin (shMALAT1), and semaphorin 3C (SEMA3C)-overexpressing (oeSEMA3C) lentiviruses were transfected alone or in combination into basilar artery VSMCs originating from IA rats. These lentiviruses were then stereotactically injected into IA rats. Results: In vitro , the overexpression of MALAT1 inhibited cell proliferation while promoting cell apoptosis and invasion; the release of TNF-α, IL-1β, and IL-6; and the transformation of IA basilar artery VSMCs from the contractile type to the synthetic type. However, the silencing of MALAT1 had the opposite effect. The silencing of MALAT1 downregulated SEMA3C, and its silencing inactivated the Smad pathway. Furthermore, SEMA3C overexpression attenuated the effects of MALAT1 silencing on IA basilar artery VSMC proliferation, apoptosis, invasiveness, proinflammatory cytokines, phenotype switching, and Smad pathway inactivation. In vivo , silencing MALAT1 reduced the release of TNF-α, IL-1β, and IL-6, decreased pathological progression, inhibited VSMC synthetic type switching, and inactivated the Smad pathway in IA rats. However, the overexpression of SEMA3C reversed these effects. Conclusion: Silencing MALAT1 represses pathological progression, inflammation, and VSMC phenotype switching by regulating the SEMA3C-mediated Smad pathway in IA.

  • Open Access

    Transradial vs Transfemoral Access for Cerebral Angiography

    by Wei Ni, Heng Yang, Jiabin Su, Ya Peng, Dengliang Wang, Zhiqing Lin, Jun Sun, Xuelin Chen, Jiyue Wang, Yi Li, et al.

    Importance: Transradial access (TRA) has emerged as a promising alternative to standard transfemoral access (TFA) for interventional cardiac procedures, but its application for examination of the cerebral circulation has not been tested in a clinical trial. Objective: To compare the efficacy and safety of TRA with TFA for diagnostic cerebral angiography. Design, Setting, and Participants: This investigator-initiated, multicenter, open-label, noninferiority randomized clinical trial with a blinded outcome assessment was conducted at 13 sites in China. Patients eligible for cerebral angiography were randomized between September 15, 2023, and November 4, 2024, with final follow-up performed on November 27, 2024. The primary analysis was performed in the intention-to-treat population; secondary analyses were performed in the per-protocol population. Interventions: Patients were randomly allocated to TRA (n = 431) or TFA (n = 430) for diagnostic cerebral angiography. Main Outcomes and Measures: The primary outcome was the success of diagnostic cerebral angiography. Secondary outcomes were success in achieving an accurate diagnosis, duration of angiography and fluoroscopy, time in bed, and patient-reported satisfaction on an 11-point visual analog scale for pain (ranging from 0 [none] to 10 [worst possible]) within 24 hours after the procedure. The noninferiority margin was an absolute difference of 5% in success of angiographic diagnosis and success of accurate diagnosis. Results: A total of 858 patients (median age, 58.4 [IQR, 52.0-67.0] years; 479 [55.8%] male) completed the trial. Success of diagnostic cerebral angiography in the TRA group was lower than that in the TFA group (392 of 431 [91.0%] vs 409 of 427 [95.8%]; difference, −4.8 percentage points [pp] [95% CI, −8.1 to −1.5 pp]; relative risk [RR], 0.95 [95% CI, 0.92-0.98]; P = .46 for noninferiority test). The success rate of accurate diagnosis was 78.9% in the TRA group vs 91.1% in the TFA group (difference, −12.2 pp [95% CI, −16.9 to −7.5 pp]; RR, 0.87 [95% CI, 0.82-0.92]; P = .99 for noninferiority test). Compared with the TFA group, the TRA group had longer median times for angiography (33.7 [IQR, 23.0-40.0] vs 38.7 [IQR, 26.0-47.0] minutes; P < .001) and fluoroscopy (10.6 [IQR, 5.6-12.9] vs 11.8 [IQR, 6.2-15.0] minutes; P = .02); the TRA group had significantly shorter median time in bed (188.4 [IQR, 3.0-180.0] vs 1079.0 [IQR, 842.0-1366.0] minutes; P < .001) and lower median pain scores (0.5 [IQR, 0.0-1.0] vs 0.7 [IQR, 0.0-1.0]; P < .001). Overall angiography complications were comparable between the groups (19 of 445 [4.3%] vs 25 of 413 [6.1%]; P = .28), but TRA had more radial artery puncture failures than TFA. Conclusions and Relevance: In this randomized clinical trial of patients undergoing diagnostic cerebral angiography, TRA was not shown to be noninferior to TFA with regard to the success rate of diagnostic cerebral angiography. Additional research, including superiority trials, is needed to clearly define the comparative benefits of TRA and TFA. Trial Registration: ClinicalTrials.gov Identifier: NCT05401669


  • Open Access

    Disengaging the Engine: Histone Deacetylases 1 and 2‐Mediated Acetylation of Hexokinase‐2 Regulates Energy Metabolism in Microglia Following Intracerebral Hemorrhage

    by Zhiwen Jiang, Heng Yang, Xinjie Gao, Zengyu Zhang, Ruiyuan Weng, Yuchao Fei, Jiabin Su, Hanqiang Jiang, Wei Ni, Yuxiang Gu

    Microglia‐mediated neuroinflammation is closely associated with the pathogenesis of secondary brain injury following spontaneous intracerebral hemorrhage (ICH). However, the relationship between immune response regulation and metabolic patterns in microglia remains unclear. Histone Deacetylases 1 and 2, a class of lysine deacetylases, regulates gene transcription by modulating histone acetylation modifications and is widely involved in various cellular activities of microglia. In this study, we observed that knockout of HDAC1/2 in microglia alleviated neurological deficits caused by ICH, preserved white matter integrity, and accelerated hematoma clearance post‐ICH. Mechanistically, we found that after ICH, microglia exhibited increased expression of hexokinase 2 (HK2) and enhanced glycolysis. HDAC1/2 knockout/pharmacological inhibition affected the acetylation level of HK2, inhibited its glycolytic activity, and promoted a metabolic shift in activated microglia from glycolysis to fatty acid oxidation. This shift was associated with reduced pro‐inflammatory responses and enhanced phagocytic activity in microglia. Enhanced fatty acid oxidation may have a detrimental effect on mitochondrial function, and HDAC1/2 inhibition simultaneously promoted mitophagy in microglia. Additionally, HDAC1/2 inhibition triggered microglial apoptosis and suppressed proliferation, ultimately leading to a reduction in microglial cell numbers. Overall, this study reveals the potential mechanisms by which targeting HDAC1/2, through acetylation modifications and transcriptional regulation, modulates microglial function and metabolism after ICH, thereby exerting protective effects.

  • Open Access

    Unraveling the Link: Ferroptosis and Its Implications in Cerebrovascular Diseases

    by Zeran Yu, Jiabin Su, Xinjie Gao, Yuchao Fei, Meng Zhang, Junhui Qi, Wei Ni, Yuxiang Gu

    Cerebrovascular diseases, encompassing a spectrum of conditions affecting the blood vessels supplying the brain, represent a significant global health burden. Among the diverse mechanisms implicated in cerebrovascular pathology, emerging evidence highlights the role of ferroptosis, a regulated form of cell death characterized by iron-dependent lipid peroxidation. The review also elucidates the molecular mechanisms underlying ferroptosis, emphasizing the pivotal role of iron, the intracellular antioxidant system, and lipid metabolism. Subsequently, it explores the growing body of literature implicating ferroptosis in the pathogenesis of various cerebrovascular diseases, including atherosclerosis, ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Special attention is given to the interplay between ferroptosis and other established mechanisms, such as oxidative stress, and inflammation. Moreover, pharmacological interventions and therapeutic strategies aimed at modulating key players in the ferroptosis cascade are explored, with a focus on their translational potential for clinical application. Finally, the review addresses current gaps in knowledge and proposes future research directions, emphasizing the need for a deeper understanding of the specific roles of ferroptosis in the pathogenesis of cerebrovascular diseases. The elucidation of these aspects holds promise for advancing our comprehension of cerebrovascular pathology and opening new avenues for therapeutic intervention in these debilitating conditions.


  • Open Access

    Endoscopic endonasal transsphenoidal management of an indirect cavernous sinus dural arteriovenous fistula: a case report

    by Zeran Yu, Zhao Ye, Jiabin Su, Yuxiang Gu, Wei Ni

    Cavernous sinus dural arteriovenous fistula (CS-DAVF) is a rare vascular disorder, with clinical manifestations largely determined by venous drainage patterns. Conventional endovascular treatment via the inferior petrosal sinus or superior ophthalmic vein may be unsuccessful when these access routes are occluded. We report a case of an CS-DAVF (Barrow type D) in which two prior endovascular attempts failed, and complete obliteration of the fistula was subsequently achieved through direct puncture of the cavernous sinus under endoscopic endonasal guidance. Postoperatively, the patient experienced complete resolution of pulsatile tinnitus and stabilization of ocular function. This case suggests that the endoscopic endonasal approach may represent a safe and effective alternative for carefully selected indirect CS-DAVF patients when standard endovascular access is not feasible.

  • Top Cited Papers
    Open Access

    Microglial Membranes Wrapped Ultrasmall Medium‐Entropy Ru Single‐Atom Nanozyme: Enhanced Catalysis for Accelerating Inflammation/Redox Microenvironment Regulation in Intracerebral Hemorrhage

    by Jiebo Li, Penghui Wei, Yuanbo Pan, Hongjia Zheng, Jiajun Hu, Qianxi Chen, Zhongyuan Shen, Yongrui Hu, Jiajun Wu, Fuxin Lin, et al.

    Intracerebral hemorrhage (ICH) causes severe secondary brain injury (SBI) via excessive inflammation and reactive oxygen species (ROS), and current treatments lack effective dual‐target efficacy. In this study, we designed a microglial membrane‐wrapped single‐atom nanozyme (PtRhIr/Ru SAN@M) by anchoring a single atom of Ru onto ultrasmall, medium‐entropy PtRhIr alloys. This design integrates two underutilized strategies, single‐atom nanozymes (SANs) and medium‐entropy catalysts, to address critical therapeutic gaps in ICH therapy. PtRhIr/Ru SAN@M exhibited enhanced catalytic activity with superior Hydroxyl radical (•OH) scavenging and superoxide dismutase (SOD)‐like and catalase (CAT)‐like performances compared to Ru‐free PtRhIr@M, enabled by electronically modulated active sites. Fluorescence imaging confirmed its ability to penetrate the blood‐brain barrier (BBB) and accumulate in post‐ICH neuroinflammatory regions. Both in vitro and in vivo experiments demonstrated that PtRhIr/Ru SAN@M repolarized microglia from the M 1 to the M 2 phenotype, disrupting the neuroinflammatory cycle and halting neuronal death. Therapeutic intervention with PtRhIr/Ru SAN@M significantly increased survival rates, restored neurological function, and enhanced spatial memory after ICH. This study pioneers the integration of SANs with medium‐entropy alloys for ICH, offering a dual‐target ROS‐inflammation regulatory strategy and a generalizable platform for ROS‐related degenerative disease therapies.


  • Fructooligosaccharides Restore Gut Function and Increase Hippocampal Short-Chain Fatty Acids to Alleviate Neuronal Apoptosis Induced by Mitochondrial Autophagy in rats with Chronic Cerebral Hypoperfusion

    by Junchen Si, Yuchao Fei, Ruiyuan Weng, Heng Yang, Wei Ni, Xinjie Gao, Yuxiang Gu

    Chronic cerebral hypoperfusion (CCH) contributes to vascular dementia (VaD) through intestinal dysfunction, reduced hippocampal short-chain fatty acids (SCFAs), neuroinflammation, mitochondrial dysfunction, and neuronal apoptosis. This study investigated whether fructooligosaccharides (FOS) alleviate CCH-induced cognitive and intestinal dysfunction and explored the potential involvement of SCFA-associated gut–brain signaling. CCH was induced in male Sprague–Dawley rats by bilateral common carotid artery occlusion (BCCAO). Rats were assigned to Sham, BCCAO, Sham + FOS, and BCCAO + FOS groups, and FOS were administered orally at 14 g/kg/day for four weeks. Cognitive function, intestinal barrier integrity, hippocampal SCFAs, neuroinflammation, apoptosis, and mitophagy were assessed. Primary neurons exposed to hypoxia were treated with SCFAs to evaluate apoptosis and mitophagy. FOS improved locomotor activity, anxiety-like behavior, spatial learning, and memory in BCCAO rats. FOS restored colonic goblet cells (P < 0.001) and ZO-1 expression (P < 0.01) and reduced intestinal TNF-α, IL-6, IL-17, and IL-33 levels (P < 0.05). In the hippocampus, FOS increased acetate and valerate levels (P < 0.05), decreased TNF-α and IL-33 expression, reduced cleaved caspase-3 (P < 0.01), preserved NeuN-positive neurons (P < 0.05), and alleviated mitochondrial injury. BCCAO-induced increases in P62, LC3B, Beclin-1, BNIP3, and NIX (P < 0.05) were attenuated by FOS, whereas PINK1/Parkin signaling remained unchanged. In primary neurons, SCFAs reduced CoCl₂-induced apoptosis and BNIP3/NIX activation and preserved MAP2/Tau-positive neuronal morphology. FOS alleviated intestinal barrier dysfunction, neuroinflammation, neuronal apoptosis, and cognitive impairment after CCH. These effects were accompanied by increased hippocampal SCFAs and changes in BNIP3/NIX-related mitophagy, supporting a potential role for SCFA-associated gut–brain signaling in FOS-mediated neuroprotection.